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Alport syndrome, historically referred to as hereditary
glomerulonephritis with sensorineural deafness and anterior
lenticonus, is a genetic disease of collagen a3a4a5(IV)
resulting in renal failure. The collagen a3a4a5(IV)
heterotrimer forms a network that is a major component of
the kidney glomerular basement membrane (GBM) and
basement membranes in the cochlea and eye. Alport
syndrome, estimated to affect 1 in 5000–10,000 individuals, is
caused by mutations in any one of the three genes that
encode the a chain components of the collagen a3a4a5(IV)
heterotrimer: COL4A3, COL4A4, and COL4A5. Although
angiotensin-converting enzyme inhibition is effective in
Alport syndrome patients for slowing progression to end-
stage renal disease, it is neither a cure nor an adequate long-
term protector. The 2014 International Workshop on Alport
Syndrome, held in Oxford, UK, from January 3–5, was
organized by individuals and families living with Alport
syndrome, in concert with international experts in the
clinical, genetic, and basic science aspects of the disease.
Stakeholders from diverse communities—patient families,
physicians, geneticists, researchers, Pharma, and funding
organizations—were brought together so that they could
meet and learn from each other and establish strategies and
collaborations for the future, with the overall aim of
discovering much needed new treatments to prolong kidney
function.
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Alport syndrome is a hereditary glomerular disease leading
almost inevitably to end-stage renal disease. The syndrome
is usually associated with sensorineural hearing loss and
distinct ocular abnormalities.1 In the early 1990s Alport
syndrome was shown to be caused by defects in collagen
a3a4a5(IV), one of the three network-forming isoforms of
type IV collagen.2 This isoform is the major collagen IV
component of the kidney glomerular basement membrane
(GBM).3 Although there have been recent improvements in
patient management, there is no cure for Alport syndrome.
The 2014 International Workshop on Alport Syndrome,
‘Shining a Light on Alport Syndrome’, was held at the Said
Business School in Oxford, UK, from January 3–5. This
meeting was organized through the concerted efforts of
patient advocacy groups from around the world. It brought
together an internationally diverse group of physicians,
geneticists, and scientists from academia and Pharma, many
of whom were not specifically Alport syndrome experts, to
learn about and discuss the latest findings regarding
diagnosis, treatment, and molecular mechanisms of disease
progression. The Workshop had four major areas of focus:
Genetics/Diagnosis, Basic Science, Treatment, and Patient
Registries/Clinical Trials. An important aspect of the Work-
shop was the ability of scientists working in laboratories to
meet individuals and families affected by Alport syndrome
and to hear firsthand their perspective about what it is like to
live with the disease. Although most of the attendees typically
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focused on the kidney disease features of Alport syndrome,
eye and hearing defects were also discussed as being very
important diagnostic and quality-of-life aspects that need to
be considered.
As reported in the Genetics/Diagnosis session and at a
special pre-meeting focused on the same topics, mutation
screening of the relevant COL4 genes is now widely available.4
Because of this, although relatively expensive, increasing
numbers of affected individuals have had their mutation(s)
identified. There are currently six databases for variants in
COL4A5, the gene affected in the X-linked, most common
form of Alport syndrome. The consortium of genetic-testing
laboratories for Alport syndrome has chosen to use the Leiden
Open Variant Database system.5 This freely accessible database
(http://www.lovd.nl/3.0/home) includes clinical features,
multiple examples of the same variant from unrelated indivi-
duals, and normal variants. The value of internationally
accessible, regularly updated variant databases is clear.
Recently, members of the Alport Variant Consortium added
500 variants to the COL4A5 database, bringing the total
number to 1900, with 1100 unique changes. The variants
include 40% missense mutations and approximately 50%
nonsense mutations. Glycine substitutions occur four times as
often as substitutions of other amino acids in the Gly-X-Y
triplet repeat collagenous segments. This is consistent with the
necessity of a Gly at every third residue to form and stabilize
the triple helical structure of the collagenous domain.
As summarized by Frances Flinter, there are several
molecular approaches for identifying variants. Although
Sanger sequencing is the gold standard, custom next-gene-
ration sequencing panels, described by Michael Yau (GSTS
Pathology, Guy’s & St Thomas’ Hospital, London, UK), plus
whole-exome and whole-genome sequencing, are rapidly
being validated and introduced into clinical practice. The
challenges associated with the interpretation of variants were
explained by Helen Storey (GSTS Pathology), as many
mutations are novel and specific to individual families.6
There are clearly founder mutations in some populations,
however—e.g. in Britain, and in Cyprus, where Constantinos
Deltas (University of Cyprus, Nicosia, Cyprus) has been
studying a large number of families in which significant renal
impairment has been noted in association with a single
autosomal COL4 mutation in some families.7 Mutation
detection within COL4 genes remains incomplete partly
because of missed rearrangements and cryptic splice site
mutations. In some cases, RNA analysis is necessary in order
to establish the potential pathogenicity of a variant. The
tantalizing prospect of extracting RNA from podocytes in
urine needs further exploration, as excreted podocytes could
be a readily available source of RNA.
The unexpected clinical variation among affected indivi-
duals in some families was discussed by Daniel Gale and Jie
Ding and could reflect variable control of hypertension and
other environmental influences; variable inheritance of
mutations or copy number variants in modifier genes could
also be important. The introduction of more comprehensive
screening technologies such as next-generation sequencing
and exome sequencing allows simultaneous screens for
mutations in other potentially relevant genes. Moin Saleem
(University of Bristol, Bristol, UK) presented a gene panel for
proteinuria potentially containing up to 37 genes for Alport
syndrome and focal segmental glomerulosclerosis, including
NPHS1, NPHS2, MYH9, and complement pathway genes.
It was noted that a clear genotype–phenotype correlation
has emerged for X-linked Alport syndrome.8,9 Large deletions
and rearrangements, nonsense mutations, and missense
mutations toward the carboxy terminus all result in more
severe disease. In addition, some amino-acid substitutions
(Arg, Glu, Asp) for Gly in the Gly-X-Y repeat collagenous
regions are more damaging.
Clifford Kashtan described the natural history and
considerable variations in the presentation of Alport syn-
drome. Indeed, a lively debate is underway regarding the
autosomal genes and the appropriate nomenclature for
individuals with a heterozygous COL4A3 or COL4A4 muta-
tion. Some such individuals have hematuria and may develop
renal impairment later in life vs. patients with classic Alport
syndrome, but they do not manifest any extrarenal features.
Some experts regard them as carriers of autosomal recessive
Alport syndrome, acknowledging that this genetic status is
associated with thin basement membrane nephropathy and an
increased risk of hypertension and renal impairment, whereas
others describe them as having autosomal dominant Alport
syndrome, although many of these patients do not fulfill the
standard clinical diagnostic criteria.10
Why is this issue so important? It is highly likely that the
current EARLY PRO-TECT Alport trial of early ACE
inhibition (www.clinicaltrials.gov; identifier NCT01485978)
will be followed by other trials, as candidate therapies emerge
from basic science research or from other clinical trials.
It is thus essential that all patients who enroll in these trials
have their diagnosis confirmed at the DNA level so that any
possible genetic factors that may influence response to
therapy are identified. Judith Savige noted that another
diagnostic test that may be useful when genetic testing is not
available is a retinal photograph that can show the charac-
teristic fleck retinopathy or an optical coherence tomography
scan that often shows temporal retinal thinning. It was also
noted that the lens capsule removed during the surgery for
lenticonus can be a good source of abnormal collagen
a3a4a5(IV) for research, although this would depend upon
the nature of the mutation.
The Basic Science aspects of the workshop focused initially
on collagen IV structure, biochemistry, and assembly of
heterotrimeric collagen IV building blocks into networks.
Billy Hudson (Vanderbilt University Medical Center, Nash-
ville, Tennessee, USA) spoke about the involvement of the
enzyme peroxidasin in catalyzing the formation of the novel
sulfilimine bond.11,12 This bond, which was explained as
important for strengthening the collagen IV network, links a
chains in one heterotrimer to those in an adjacent hetero-
trimer via conserved Met and Lys residues. A phylogenetic
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investigation of this finding revealed that the sulfilimine
bond is an ancient evolutionary adaptation first apparent in a
subset of Cnidarians that was accompanied by the appear-
ance of the peroxidasin gene.13 Peroxidasin’s enzymatic
function was shown to involve the production of a bleach-
like chemical that could theoretically be detrimental to the
basement membrane if overproduced; this is one potential
novel mechanism that could explain the GBM splitting that
invariably occurs in Alport syndrome.
Three important aspects of normal GBM (Figure 1) and
Alport GBM composition were addressed. Rachel Lennon
(University of Manchester, Manchester, UK) described a
brute-force high-resolution mass spectrometric analysis of
isolated total glomerular extracellular matrix that revealed
the presence of many proteins previously unknown to be
resident in glomeruli.14 Some of these will certainly be
localized to the GBM (rather than mesangium) and could
be secondarily involved in Alport GBM pathology. One
particular standout localized to GBM is type VI collagen,
which is known to be important in skeletal muscle but could
act in the GBM to modify collagen IV assembly or function.
In fact, collagen VI has already been shown to be increased in
human Alport GBM.15
Jeffrey Miner presented rescue studies of Col4a3 /
Alport mice carrying a doxycycline-inducible Col4a3 trans-
gene. This work provided a proof-of-principle demonstration
that conversion of an abnormal Alport GBM containing only
the collagen a1a1a2(IV) network to one also containing the
missing collagen a3a4a5(IV) network is possible.16 Restoration
of the missing collagen IV network at various ages, as late as
7.5 weeks, was shown to slow down kidney disease progression
and extend the life span. It was reported that, the earlier the
induction with doxycycline, the longer the life span.
As presented by Dominic Cosgrove (Boys Town National
Research Hospital, Omaha, Nebraska, USA), the presence of
ectopic laminin a2 in the Alport GBM, secreted by mesangial
cell processes that invade the peripheral capillary wall,17
activates phosphorylation of focal adhesion kinase in
podocytes, which causes detrimental foot process changes.
This identifies focal adhesion kinase phosphorylation as a
potential drug target for slowing down Alport syndrome. The
involvement of integrin-mediated signals and the pathogenic
effects of hypertension suggest that increased biomechanical
strain18 due to the defective GBM is a major factor in
promoting podocyte injury.
Concepts thought by the collective basic science group to
be important for the future included the following: defining
targets for therapy; developing additional animal models to
better model human mutations; and deriving cell lines from
Alport mice and/or patients to gain a better understanding of
how changes in the GBM cause changes to the overlying
podocytes, which appear to be key to disease progression.
There were two major targets discussed for developing
new treatments. The first was the defect in the GBM itself.
Although most agreed that gene repair, gene replacement,
protein replacement, or podocyte replacement therapies should
be effective if applied early enough during the course of disease
(again demonstrating the importance of early diagnosis), the
technical hurdles are significant, as found previously in stem
and blood cell infusion studies,19 gene transfer studies with
pigs20 and, as mentioned by Karl Tryggvason (Karolinska
Institute, Stockholm, Sweden and Duke NUS, Singapore City,
Singapore), in a canine Alport model.
The second target discussed at length consisted of the
collective ‘molecular and cellular symptoms’ that result from
the primary defect in the GBM. Inhibition of focal adhesion
kinase phosphorylation was suggested by Dominic Cosgrove
as a therapy to protect podocytes, as was inhibition of
collagen receptors DDR1 and integrin a2b1, the activation of
which exacerbates Alport disease progression in mice,21,22 as
reported by the group of Oliver Gross. Studies on the effect
of attenuating interstitial fibrosis on survival of Alport mice
have yielded mixed results, with some studies showing
improved survival and others showing no improvement.23
It was agreed that efforts aimed at slowing down disease
progression should focus on both the glomerular and the
tubulointerstitial compartments, with protection of
podocytes as a high priority. There was frequent mention
during the Workshop of findings in mice showing that the
same mutation can result in highly variable rates of
progression to kidney failure, reinforcing the concept that
genetic background has a significant role.24,25 As mentioned
above, next-generation sequencing could be beneficial in
identifying the modifier genes responsible and hopefully
reveal additional pharmacological targets. Infusion of
amniotic fluid–derived stem cells into Alport mice was
reported by Laura Perin (University of Southern California,
Los Angeles, California, USA) to dampen angiotensin II
receptor activation and attenuate fibrosis, but without any
effect on GBM composition.26 The targeting of the pro-
fibrotic microRNA-21 was also discussed by Oliver Gross as a
Figure 1 | The normal human kidney glomerular basement
membrane (GBM) contains primarily collagen a3a4a5(IV), which
is defective or missing in Alport syndrome. A frozen human kidney
section was stained in red for COL4A4, representing the a3a4a5(IV)
network, and in green for collagen a1a1a2(IV). The GBM and a few
tubular basement membranes are enriched in collagen a3a4a5(IV).
The a1a1a2(IV) network is detected primarily in the mesangial matrix
and in tubular basement membranes.
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very promising new approach to treatment.27 Although most
of the attendees were focused on mouse models, the existing
dog models of Alport syndrome should also be considered for
the testing of new therapies, given their larger size and longer
life span compared with mice.
Nevertheless, the generation of new mouse models to
better mimic human Alport syndrome was identified as a
short-term need. This is because most mouse models are
autosomal Col4a3 or Col4a4 gene knockouts, whereas most
patients have missense mutations in the X-linked COL4A5
gene, and many of these mutations are Gly substitutions that
likely impair trimer assembly, secretion, network formation,
or all three processes. Given the improved technologies for
manipulating the mouse genome, as presented by Paul Potter
(MRC Harwell, Oxfordshire, UK), generation of a few
additional animal models was considered to be a reasonable
goal for the near future. Two new mouse models were
presented at the Workshop: one, generated by Constantinos
Deltas (University of Cyprus, Nicosia, Cyprus), has a targeted
Gly substitution in COL4A3 that is analogous to a human
mutation (G1334E) common in Cyprus;28 and one, isolated
at The Jackson Laboratory, has a spontaneous splice site
mutation in Col4a4 that results in exon skipping and
production of defective a3a4a5(IV) trimers.29
Data presented by Constantinos Deltas suggest that
podocyte production of defective collagen IV chains can
cause endoplasmic reticulum stress and perhaps exacerbate
injury;28 chaperones that promote protein folding could
therefore be therapeutic in some settings.27 Developing the
appropriate tools for high-throughput testing of these or
other classes of compounds in either cell or zebra fish models
was thought to be an important goal for the future. Finally,
the establishment of a ‘toolbox’ of reagents, including well-
characterized collagen IV antibodies and cDNAs, for
scientists working on Alport syndrome was proposed as an
excellent mechanism to facilitate research efforts.
In the Registries and Clinical Trials Session it became clear
that in Alport syndrome the main therapeutic priority is for
treatments that are able to delay the progression of chronic
kidney disease. For most patients, this progression occurs
during childhood or adolescence; therefore, future trials of
novel drugs are likely to be conducted chiefly in the pediatric
and young adult setting. The vulnerability of this target
population and the need for prolonged treatment suggest
that evidence of safety for new drugs will be particularly
important. Colin Baigent described experiences in other areas
of medicine, indicating that most drug treatments have at
best moderate effects (e.g., a 15–20% reduction) on major
clinical outcomes30 (e.g., progression to end-stage renal
disease), implying the need for substantial sample sizes in
new trials. For these reasons—that is, the need for large trials
to provide robust evidence on both safety and efficacy—the
Alport research community needs to establish appropriate
infrastructure to facilitate such studies. At present, it is
difficult to identify large numbers of eligible patients, as
exemplified by the experience of the ongoing EARLY PRO-
TECT Alport trial31 (presented by Oliver Gross) assessing the
effects of ramipril among children with no or minimal pro-
teinuria. Current clinical practice recommendations focusing
on early identification of proteinuria and treatment with
angiotensin blockade10,32 were supported by the Workshop
participants.
Infrastructure to support trials implies an ability to
identify and invite potentially eligible patients, and this in
turn requires that patients are registered, phenotyped,
genotyped, and actively followed up in national registries.
As insufficient numbers of patients are available in any single
country, a further requirement is that national registries are
linked via a coordinating center, allowing simultaneous study
of patients in multiple countries. Currently, there are
registries of patients with Alport Syndrome in the United
States (Alport Syndrome Treatments and Outcomes Registry;
http://www.alportregistry.org), the United Kingdom (Renal
Rare Disease Registry; https://www.renalradar.org), China
(China Alport Syndrome Treatments and Outcomes Regis-
try), the European Alport Registry, Italy (the Italian Alport
National Registry and Biobank), and France (the French
National Rare Disease Registry). In total, these registries
include around 3000 individuals.
A review of these registries, as summarized by Parminder
Judge, indicated that there is substantial overlap in the
information collected in them, but that a major limitation
if they are to be utilized to support trials (and other studies)
is that they do not typically seek regular follow-up. An
exception is the UK RaDaR registry, which links to ‘Renal
Patient View’ (RPV; https://www.patientview.org). RPV
incorporates laboratory results from participating UK renal
clinics; thus, linkage between RaDaR and RPV allows
phenotypic and genotypic information to be linked with
renal functional data longitudinally.
The Alport syndrome research community present at the
meeting agreed that there is a need to: (i) expand coverage of
existing national registries (as only a fraction of registrants
are likely to be eligible and willing to enter new trials);
(ii) improve data collection in existing registries (especially
with regard to arranging for regular follow-up information to
be obtained); (iii) identify new countries where collections of
Alport syndrome patients exist that could be incorporated
into registries; (iv) build the infrastructure necessary to
allow collaboration between registries in future trials and
epidemiological studies; and (v) seek cooperation with
companies that have promising agents for the treatment of
Alport syndrome and explore practical technologies to allow
international studies in conjunction with them.
Representatives from National Patient Organizations were
in attendance from Australia, China, France, Germany, Italy,
The Netherlands, Spain, United Kingdom, and the United
States. The primary objective of these organizations was to
discuss ways of working together to support research that will
result in an improved quality-of-life for individuals and
families living with Alport Syndrome. Susie Gear from
Alport UK (http://www.alportuk.org), Daniel Renault from
682 Kidney International (2014) 86, 679–684
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AIRG-France (http://www.airg-france.fr), and Sharon Lagas
from the Alport Syndrome Foundation (USA; http://www.
alportsyndrome.org) presented personal perspectives on how
this disease affects their lives and those of their constituencies
by afflicting multiple family members in every generation
with kidney failure and hearing loss. Research perspectives
and strategies were also presented for each organization and
included the need for patient input into research priorities,
the use of seed funding to facilitate progress, and develop-
ment of strategies to promote collaborations on larger
funding initiatives.
Patient organizations have a pivotal role in educating their
lay communities about current research and the value of
patient involvement. At the Workshop, patient representa-
tives learned about current research, listened to experts
discuss and debate future strategies and priorities, and
interacted with researchers to obtain answers to questions of
interest to the patient community. Collaboration between the
patient and research communities is critical for research on a
rare disease such as Alport syndrome. This Workshop served
to both strengthen existing collaborations and expand
collaborations on an international scale. The development
of an international alliance for Alport syndrome involving
both the patient and research communities is a potential
outcome of the Workshop.
Patient organizations recognize they can support research
by recruiting patients and communicating the essential role of
registries and clinical trials to foster more patient participa-
tion. In addition, patient organizations can communicate to
the research community those patient concerns that are not
being addressed for development of future research priorities.
For example, when surveyed about their priorities for research,
the majority of patients identified hearing and psychological/
social support as important, but these are areas often
overlooked in Alport syndrome research. Innovative work-
shops such as this that combine patient, clinical, scientific, and
industry aims serve to foster collaboration and strategic
planning that is critical to advance research. Future objectives
to build upon the success of this Workshop include:
 Strengthening the patient communities in the respective
countries by recruiting more patients and working with
local clinicians, geneticists, and registries (or starting a new
or joining an existing registry)
 Expanding patient organizations to additional countries
 Organizing at an international level to work strategically to
support collaboration between national patient registries
and research initiatives
 Developing national meetings with patients, clinicians, and
scientists to foster collaboration, communication, and
education
 Supporting future international workshops that bring
together all stakeholders in the Alport syndrome community
(patients, clinicians, geneticists, scientists, and Pharma).
In conclusion, the 2014 International Workshop on Alport
Syndrome was not only able to ‘shine a light on Alport
syndrome’, but the interactions among the various stake-
holder groups were very effective at ‘motivating, energizing,
and inspiring’ (these were actual responses on the Workshop
feedback forms). Closing remarks by Karl Tryggvason on the
history of Alport syndrome research and the prospects for
future therapies and by Ted Bianco (Acting Director of the
Wellcome Trust, London, UK) on prospects for funding
international collaborations were especially encouraging.
The participants agreed to try to translate the enthusiasm
generated at the Workshop into an international program of
collaborative research and funding proposals in the near
future. This will involve both young and senior scientists and
clinicians combining their efforts to find new strategies to
protect the injured kidney, ear, and eye from additional
damage and to eventually find a cure to prevent or reverse the
disease. Several promising new therapies, all with different
targets and mechanisms of action, were discussed as having
potentially additive benefits to existing therapies and perhaps
to each other. This provides hope that Alport syndrome can
be prevented or attenuated in most patients by such a
multimodal therapy that will likely continue to include ACE
inhibition as the basic standard of care.
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